Management to share updates on company’s non-invasive cancer detection programs
Bluestar Genomics, Inc., an early cancer detection company leading the development and commercialization of next-generation liquid biopsy approaches initially focused on non-invasive detection of high-mortality cancers, today announced that management will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 12 at 4:30 p.m. ET.
This will be Bluestar Genomics’ first J.P. Morgan Healthcare Conference presentation, which will be followed by a 10-minute question-and-answer session and one-on-one meetings with investors. Samuel Levy, Ph.D., acting chief executive officer and chief scientific officer at Bluestar Genomics, will provide an update on the company’s development and commercialization efforts for its non-invasive epigenomic tests.
“We are pleased to be invited to present at the J.P. Morgan Healthcare Conference to share our technology story and commercialization roadmap with the investment community,” said Samuel Levy, Ph.D., acting chief executive officer and chief scientific officer at Bluestar Genomics. “As we continue to focus on the deadliest types of cancer that currently lack early detection protocols, 2022 proves to be a transformative year for our company and industry as we seek to improve non-invasive cancer detection.”
For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybersecurity, go to AI-Techpark.com.
